Graticule Appoints Patrick Wulf Hanson as Chief Alliance Officer for EU Operations
5.9.2023 17:00:00 EEST | Business Wire | Press release
Graticule, a Real World Data CRO that conducts life science research and development projects with both USA and International data partners, is pleased to announce the onboarding of Patrick Hanson as the Chief Alliance Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230831939371/en/
Patrick Wulf Hanson (Photo: Business Wire)
Daniel Poscover, Founder and CEO of Graticule, mentioned, “We are thrilled to welcome Patrick to our leadership team. With his vast experience in stakeholder management, engagement, and close interactions with Key Opinion Leaders (KOLs) and regulatory authorities, I am confident that we can broaden our EU operations to a much larger network.”
Patrick has over 30 years of experience in the pharmaceutical industry, consultancy, and academia. He previously served as Vice President for Real-World Data Alliances Europe at Lumanity, Head of Real World Data Strategy Europe and Canada at Parexel, Director of Real-World Analytics & Solutions Nordics (and Head of Denmark) at IQVIA, Nordic medical director at McCann Health Nordic, Scientific Director at Cohn & Wolfe and Molecule Consultancy, and Director of Global Product Safety, Regulatory Affairs Officer, and Corporate Branding at Novo Nordisk. Before his industry work, Patrick held research and teaching positions in Sweden, Denmark, and the USA. He has also authored textbooks and peer-reviewed articles.
Patrick's vast network and diverse European experience will help introduce innovative business strategies and foster collaborations for Graticule's European operations. Patrick believes that his ability to create sustainable relationships and alliances, stakeholder engagement, communicate advanced medical content to any audience, and create value for customers and patients will help Graticule in becoming a leading player in the European market.
To learn more, visit Graticule.
About Graticule
Graticule is a Real World Data CRO that conducts life science research and development projects with both USA and International data partners. The company focuses on establishing relationships, tools, and expertise to overcome traditional barriers that have limited the applications of medical data. Graticule solutions include comparative effectiveness studies, surveillance, patient identification, clinical trial recruitment, and an automated data transfer to Electronic Data Capture systems. The company differentiates itself by focusing on timely access to relevant patient data through close engagement with both Graticule Research Network and project-specific data partners. The result of the approach is a team that can rapidly leverage advanced data sets such as clinical notes, imaging, genetic testing, and structured clinical data and can scale research to large populations over time. Our solutions include Graticule Study Source, Graticule Patient Finder, and Graticule CLEHR.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230831939371/en/
Contact information
Kyle F. Conley
Vice President of People Operations, Privacy Official
kconley@graticule.life
(617) 412-0999
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom